# A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In P

Source: https://onco.cc/trials/nct06710288/  
OnCo record `nct06710288` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Gemcitabine, Nogapendekin alfa inbakicept in ovarian cancer, run by ImmunityBio, Inc., now recruiting.

## Summary

A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer is a phase 2 interventional study registered as NCT06710288 by ImmunityBio, Inc., with 20 participants planned, started 2024-11-06 and due to reach its primary completion in 2027-05. Interventions recorded: Gemcitabine, N-803, M-CENK. Conditions listed: Platinum-resistant Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06710288
- Phase: 2
- Setting: A Phase 2, Open-label, Single-arm Study Of Autologous Memory Cytokine Enriched Natural Killer (M-CENK) Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer
- Sponsor: ImmunityBio, Inc.
- Enrolled: 20

## Sources

- ClinicalTrials.gov NCT06710288: https://clinicaltrials.gov/study/NCT06710288

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Nogapendekin alfa inbakicept](https://onco.cc/drugs/nogapendekin-alfa/)
- companies: [ImmunityBio](https://onco.cc/companies/immunitybio/)

---
JSON: https://onco.cc/api/v1/entities/nct06710288.json